Loading clinical trials...
Loading clinical trials...
The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing corneal transplantation.
As a secondary objective, this study also aims to establish the corneal and anterior chamber concentration of ranibizumab when delivered subconjunctivally at the limbus in patients undergoing corneal transplantation. The effects of ranibizumab on corneal epithelial healing will be examined following adjunctive use in corneal transplantation. Finally, clinical characteristics including recurrent corneal neovascularization will be studied.
Age
18 - 110 years
Sex
ALL
Healthy Volunteers
No
Bascom Palmer Eye Institute
Miami, Florida, United States
Start Date
October 1, 2008
Primary Completion Date
August 1, 2011
Completion Date
March 1, 2012
Last Updated
July 11, 2017
5
ACTUAL participants
Ranibizumab
DRUG
Lead Sponsor
University of Miami
Collaborators
NCT04787471
NCT00555594
NCT05659940
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions